Research
Hormonal
Tirzepatide, a dual GIP/GLP-1 receptor agonist, demonstrates significant potential for achieving prediabetes and type 2 diabetes remission through superior glycemic control and weight loss compared to other GLP-1RAs.
Ask your doctor about tirzepatide, a dual-acting medication that targets both GIP and GLP-1 receptors. It has shown exceptional results in achieving remission and significant weight loss, potentially offering a path to stopping other diabetes medications.
GoodSupportsHIGH confidence
Tirzepatide: In the 15 mg group, HbA1c decreased by 2.07%, and body weight decreased by 9.5 kg; the remission rate of prediabetes was 95.3% vs. 61.9% (placebo). These data suggest that tirzepatide has notable therapeutic effects on obesity, as well as aids in achieving prediabetes remission.
Why this rating
Supported by large-scale RCTs (SURPASS-1, obesity trial).
Source
Type 2 diabetes remission: multidimensional pharmacological strategies and future perspectives
Yang Liu et al. · Frontiers in Endocrinology · 2025
DOI 10.3389/fendo.2025.1687601
narrative_review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Short-term intensive insulin therapy (SIIT) using continuous subcutaneous insulin infusion or multiple daily injections for 2-3 weeks can induce sustained drug-free remission in newly diagnosed type 2 diabetes patients by restoring beta-cell function and reducing glucotoxicity.Good
- Combination therapies involving GLP-1 receptor agonists (GLP-1RAs) and insulin, or comprehensive metabolic interventions including metformin, significantly increase diabetes remission rates compared to standard care.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →